Aiosyn, a spin-off from Radboudumc, has received an investment from LUMO Labs. The Nijmegen-based company is developing an AI platform that supports pathologists with more precise and efficient clinical diagnoses. Oost NL is a co-investor.
Pathology is indispensable in the diagnostic process of many diseases, such as cancer. Now this involves tissue examination with a microscope. Globally, there is a shortage of pathologists and an increasing demand for efficiency and consistent quality in the assessment of images. Diagnosis has a major impact on the treatment to follow. The better the diagnosis, the better the patient can ultimately be helped. Aiosyn's AI platform helps pathologists do just that.
Algorithms for clinical practice
Aiosyn originates from the Computational Pathology Group of the Radboudumc led by Jeroen van der Laak. Van der Laak is also scientific director (CSO) of Aiosyn. The Nijmegen-based company's technology uses "neural networks" to identify abnormal tissue patterns such as cancer with tremendous accuracy. Aiosyn brings these algorithms from research to clinical practice to improve the speed and quality of diagnostics in pathology. The investment from LUMO Labs and Oost NL will be used to expand pathologists' access to artificial intelligence.
Investment enables faster growth
Patrick de Boer, co-founder and managing director (CEO) of Aiosyn, is pleased with the investment in the company: "With LUMO Labs as lead investor and Oost NL on board, a network of knowledge and expertise is created to grow our company faster. In terms of the entrepreneurial and business aspects of this collaboration, we are on the same page. Oost NL has helped us early on in the stage to focus our business case and make our company investor-ready. Partly because of that, we can take this step."
Accessible, scalable technology
"The Aiosyn platform increases disease knowledge and the quality of healthcare," says LUMO Labs founding partner Andy Lürling. "The highly scalable technology will give physicians around the world, including in developing countries, access to in-depth expertise and diagnostic support. Björn Schaap, investment manager Health at Oost NL: "With their artificial intelligence technology, Aiosyn is in an excellent position to connect with the growing digitalization within the healthcare sector and this investment will allow the Nijmegen-based company to expand the team and further develop its products and services." Dennis Lammers, CFO of Radboudumc Holding added: "Sustainable, inclusive healthcare requires accessible diagnostic tools that are highly reliable, effective and efficient. As Radboudumc Holding, we see great potential in Aiosyn's technology and team for the future of healthcare."
Related news items
Liver tumors irradiated from inside can be followed live from outside17 February 2022
A Dutch research team from Radboud University Medical Center has visualized the injection of radioactive microspheres during treatment of a patient with liver tumors ‘live on screen’.read more
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
Large AI project receives over €95 million for ten years of public-private research23 September 2021
The Dutch Research Council (NWO) is to fund two consortia for a period of ten years. Radboudumc participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboudumc leads five of these eight labs.read more
New start-up Patholyt will bring AI research into pathology diagnostics21 September 2021
Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.read more
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview22 July 2021
Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.read more
Miljoenen voor kennis- en investeringsconsortium op het gebied van AI14 April 2021
Een kennis- en investeringsconsortium met het Radboudumc heeft acht miljoen euro subsidie gekregen om innovatie op het gebied van Artificial Intelligence (AI) versneld naar de markt te brengen.read more